GlassScriptPhysician profile
Robin Snellings
NPI 1235765199
$2,109.53
in general payments reported to CMS, 2019-2025
11 companies · $683 in 2025
The $683 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $103 · 2023: $313 · 2024: $1,010 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,006.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $493.33 | 2024-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Abbvie INC. | $427.52 | 2023-2025 | Mavyret, Teflaro |
| Shionogi INC | $225.06 | 2022-2025 | Fetroja |
| Viiv Healthcare Company | $221.47 | 2024 | Apretude |
| Insmed, INC. | $143.93 | 2024-2025 | Arikayce |
| Angiodynamics, INC. | $130.24 | 2025 | Angiovac |
| Gilead Sciences, INC. | $130.05 | 2024 | |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| La Jolla Pharmaceutical Company | $104.37 | 2024 | Xerava |
| Astellas Pharma US INC | $86.13 | 2023 | Cresemba |
| Merck Sharp & Dohme LLC | $22.43 | 2023 | Recarbrio, Dificid, Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Snellings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.